Kornimate/medical-research-clean huggingface dataset:
adherence to antiretroviral therapy in hiv infected individuals in assiut governorate, egypt

Conditions: HIV Infections

Summary: egypt is a hiv low prevalence country but between 2010 and 2019 newly infected cases have more than quadrupled, and the rise continues at an alarming pace. maintaining over 95% adherence level among the plhiv in developing countries is a crucial issue to maintain viral suppression, to minimize hiv related morbidity and mortality. the present study aims to identify the level of adherence and the factors influencing adherence to art in assiut governorate. to the best of our knowledge, no previous studies on adherence to antiretroviral therapy and its associated factors in hiv infected individuals were done in egypt.

egypt is a hiv low prevalence country but between 2010 and 2019 newly infected cases have more than quadrupled, and the rise continues at an alarming pace. according to the who country profile in 2021, 65% of people living with hiv (plhiv) know their status, there is no statistic on viral load suppression, or the level of adherence to treatment among those who are under care. to achieve optimal results from antiretroviral therapy (at least 95%), high levels of patient adherence to art is essential. therefore, enhancing art coverage is a principal strategy to end hiv/aids. medication adherence, which can be defined as the extent to which a patient's medicine-taking behavior corresponds with agreed instructions from a health care provider, is essential for realizing the potential benefits of most medication-based treatment. many patients, especially those with chronic diseases, experience difficulties in adhering to a recommended treatment plan. medication non-adherence, with average rates of those affected being between 30 and 50%, is a major challenge in the real-life treatment of these patients . despite several advances in art for human immunodeficiency virus in the last decades, non-adherence continues to be a critical phenomenon in the treatment of these patients. not only short-term virological response will be poor, but low drug concentrations also dramatically accelerate development of drug-resistance. so, maintaining over 95% adherence level among the plhiv in developing countries is a crucial issue to maintain viral suppression, to minimize hiv related morbidity and mortality.

Eligibility criteria:
inclusion criteria: * hiv +ve adults identified and listed by the hiv/aids national program in assiut governorate. aged 18 years old and more. exclusion criteria: * prisoners children patients aged less than 18 years old
morpho-functional cardiac modifications in treated mutated transthyretin cardiac amyloidosis

Conditions: Cardiac Amyloidosis

Summary: cardiac amyloidosis (ca) is characterized by a long subclinical phase characterized by deposition of amyloid fibrils in atria, valves and walls of ventricles. longitudinal dysfunction of the left ventricle (lv) with preserved ejection fraction (ef) is the early phase of ca. longitudinal dysfunction mainly involves the lv basal and middle segments with less involvement of the distal segments (apical sparing). strain echocardiography (ste) measures myocardial deformation. the technique has been shown to be sensitive for early detection of impaired systolic function and for the study of ca. additionally, cardiac efficiency (myocardial work) can be derived from myocardial strain data analysis. in the year 2018, "rna interferences" (patisiran and inotersen) were included in the list of compassionate therapeutic use programs for exclusive use for the treatment of adult patients with hereditary amyloidosis neuropathy. the aim of our study is to evaluate the morpho-functional modifications with rna interferences.

transthoracic echocardiographic images are recorded in the available ultrasound units (vivid 7 and vivid 9, ge ultrasound, horten, norways and mylab - esaote, genoa, italy). the diameters and the wall thicknesses are measured according to the insurance of the american society of echocardiography. the images obtained with apical view and in format 4 bedrooms with frame rates (70-80 frames / s) - stored for three cardiac cycles in cine-loop format - will be used for evaluate off-line to evaluate left ventricle deformation in the longitudinal and radial direction, basalelateral, and top segments (post processing) through software already in use and available (suitestenza, esaote, florence, italy and ge ultrasound, horten, norway).

Eligibility criteria:
inclusion criteria: * presence of data obtained from historical records of patients who retrospectively met the prescriptive (neurological) criteria and received the prescription of the drugs in question (rna interferences) having * cardiological evaluation (examination ecg, echocardiography) at the time of prescription * cardiological evaluation (examination ecg, echocardiography) evaluated six months after therapy, * cardiological evaluation (examination ecg, echocardiography) evaluated 12-18 months after therapy, exclusion criteria: * it wasn't possible to putatively confirm the reasonable shipment of the innovative therapy prescribed * it wasn't possible to putatively confirm the reasonable shipment of conventional therapy prescribed (background therapy)
clinical-genetic variation in gaba/alcohol sensitivity

Conditions: Alcoholism

Summary: the purpose of the study is to better understand how genetic factors influence individual sensitivity to alcohol.

we want to find out if there are specific characteristics of a person's genes which will cause them to respond differently to alcohol. genes are parts of the chromosomes found in the cells of our bodies which control our physical characteristics such the color of our hair, eyes, and other features. genes are made up of molecules called "dna" which carry the genetic information we receive from our parents. just as genes control our physical characteristics, differences in genetic information may also explain why some people are more sensitive to alcohol or have problems drinking too much.

Eligibility criteria:
inclusion criteria: * the subject is male or female with at least one hispanic birth parent of mexican ancestry, 21-25 years of age, and able to read the english-language consent form. * the subject self-reports current use of 3-30 standard drinks * the subject is in good physical health as determined by history, physical and laboratory studies of hematology and chemistry * the subject has a body mass index (bmi) between 20-28 * the subject is not concurrently using psychoactive medication or illicit drugs * if subject is female, she is not pregnant (determined by weekly urine pregnancy screens), is practicing barrier or chemical methods of birth control, and not nursing babies exclusion criteria: * the subject meets dsm-iv criteria for any lifetime history of alcohol dependence, or dependence or abuse on any other drug in the past two years excepting tobacco dependence * the subject currently meets dsm-iv for any other psychiatric (axis i) disorder, excepting tobacco dependence * the subject cannot consistently provide alcohol-free breath samples and drug-free urine samples * the subject uses \> 20 cigarettes per day or \> 500 mg caffeine per day * the subject's physical exam, lab tests, and medical histories indicate medical illness requiring treatment or interacting with the alcohol or benzodiazepine treatments * the subject has a sleep apnea or narrow angle-glaucoma (contraindications for benzodiazepines) * the subject reports extreme hypersensitivity or allergic reactions to benzodiazepines or unusual hypersensitivity to multiple medications * the subject is unwilling or unable to consent to all experimental procedures including confidential family history interviews and genetic testing specified by the protocol

Keywords: alcohol gaba genetic variation
acandis stenting of intracranial stenosis - registry

Conditions: Intracranial Stenosis

Summary: assistent is designed to collect comprehensive information on technical and clinical safety of the use of credo® stent together with the neurospeed® pta balloon catheter in clinical practice in an open registry.

assistent is subdivided into two components. the first part only requires recording of data acquired in routine clinical practice during the treatment of patients with intracranial stenosis with the self-expandable credo® stent until discharge. this comprises demographic data, data concerning the qualifying clinical event, limited data on medical history and medication, information about the intervention including technical success and periprocedural complications or events, and information about events and clinical status during the in-hospital treatment until hospital discharge. the second part of the registry consists of a follow-up visit 30 days after the interventional procedure which will be conducted outside of clinical practice.

Eligibility criteria:
inclusion criteria: - treatment with credo® for symptomatic atherosclerotic intracranial artery stenosis (see product ifu) exclusion criteria: * there are no specific exclusion criteria (see product ifu)
once-nightly sodium oxybate for treatment of excessive daytime sleepiness and cataplexy in narcolepsy

Conditions: Excessive Daytime Sleepiness; Cataplexy; Narcolepsy

Summary: the purpose of this study is to determine whether once-nightly ft218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.


Eligibility criteria:
inclusion criteria: 1. male or female subjects 16 years of age or older 2. willing and able to give written informed consent for study participation. for young adults (16 and 17 years old) who have not reached the age of majority they must be capable of giving assent and consent from a legally authorized guardian must be obtained, as required by local laws and regulations 3. documented evidence of a diagnosis of nt1 (type 1 narcolepsy) or nt2 (type 2 narcolepsy) as, in part, determined by an overnight psg (polysomnography) and next-day mslt (maintenance of sleep latency test) with 2 or more soremps (sleep onset rem) with mean sleep latency in the pathological range i.e. \< 8 minutes and meeting the nt1 and nt2 as defined by the international classification of sleep disorders -3 criteria. 4. current continuing presence of eds (excessive daytime sleepiness) as defined by subject report for the last 3 months and an ess (epworth sleepiness scale) \> 10 5. for nt1 only, current continuing presence of cataplexy as defined by subject report for the last 3 months 6. subjects may use concomitant stimulants, but must comply with the following: 1. they must be on a stable dose of stimulants for at least 3 weeks prior to starting the screening process for this study; and 2. they must use the same stimulant regimen throughout the entire study period, including during screening and posttreatment periods 3. they must discontinue all anti cataplexy drugs 7. addition inclusion criteria per protocol exclusion criteria 1. any prior use of sodium oxybate is allowed in the study but within the following exclusions: 1. previous dosing must have been limited to no more than 4.5g per night 2. patient should not have taken sodium oxybate for more than 2 weeks. 3. all previous dosing must not have occurred within the last year prior to entry to the study. 2. current use of sodium valproate 3. any use of the following prohibited medications for the duration of the clinical study: 1. anticonvulsants 2. clonidine 3. ssris (selective serotonin re-uptake inhibitors) and serotonin and norepinephrine re-uptake inhibitors (snris) 4. maois (monoamine oxidase inhibitors) 5. tcas (tricyclic antidepressants) 6. hypnotics 7. anxiolytics 8. sedating antihistamines 9. antipsychotics 10. other experimental medications designed to treat narcolepsy, cataplexy or any other condition 4. treatment with any investigational products within 3 months before study enrollment 5. any drug known to affect sleep-wake function. concomitant stimulant use is permitted 6. additional exclusion criteria per protocol
post covid-19 vaccination analysis in healthcare worker recipients

Conditions: Covid19; Vaccine Reaction

Summary: this research study is studying how healthcare worker recipients react after receiving vaccinations for covid-19. the objective of the study is to evaluate the immune response to covid-19 vaccination. the immunity will be evaluated over time by measuring serum semi-quantitative sars-co-v2 igg from blood specimens and analyzing vaccine reaction data. sars-cov-2 is the name for the virus responsible for covid-19 infections. igg, immunoglobulin g, is an antibody found in the blood that protects against bacterial and viral infections. study subjects will also be asked to report physical reactions they may have experienced related to vaccinations.

as some of the first recipients of sars-cov-2 vaccines under emergency authorization use, healthcare workers represent a diverse subpopulation, that are now moving through the immune response to the pfizer and moderna mrna vaccines. as individual responses may vary, this provides an opportunity to evaluate levels of igg response in relation to age, gender, comorbidities and other factors that may influence immunity. we recognize that, though this is only part of the immune response that may be protective for severe covid-19 disease, it is a first step in understanding the level and durability of post vaccination sars-cov-2 antibodies. this small, pilot study will evaluate the immune response over time by measuring serum semi-quantitative sars-cov-2 igg from healthcare vaccinees at various timepoints. a high-level review of reactions related to the vaccinations will be performed with the same population of healthcare workers.

Eligibility criteria:
inclusion criteria: * signed informed consent for study * current employee or active member of the medical staff of huntington hospital, pasadena, ca, (must have valid hospital identification) * must have completed vaccination regimen (two doses if required) no more than 8 weeks ± 5 days before enrollment * must have completed, valid vaccination card, if vaccinations received at a center other than huntington hospital * able to read english, sign consent form and complete on-line surveys exclusion criteria: * huntington hospital employees on leave of absence * anyone not able/willing to provide blood specimens and respond to surveys for the 52-week study period

Keywords: sars-cov-2 vaccination antibody formation
a phase i study of tq-b3456 on tolerance and pharmacokinetics

Conditions: Non-small Cell Lung Cancer

Summary: to study the pharmacokinetic characteristics of tq-b3456 in the human body, recommend a reasonable regimen for subsequent research.


Eligibility criteria:
inclusion criteria: - progressive or metastatic non-small cell lung cancer that diagnosed pathologically or cytologically diagnosed patients who have received egfr tyrosine kinase inhibitor monotherapy (e.g., gefetinib, erlotinib, ecotinib, afatinib) for disease progression egfr t790m mutation was confirmed ecog ps≤1 adequate blood cell counts, kidney function and liver function patients should participate in the study voluntarily and sign informed consent exclusion criteria: patients with non-small-cell lung cancer who have received osimertinib or other raw materials or preparations for egfrt790m mutant drugs hypertension (systolic bp ≥140 mmhg, diastolic bp ≥90 mmhg) still uncontrollable by one medication; hepatitis b virus patients with active replication (dna\> 500 cps / ml), hepatitis c; patients with immunodeficiency, including hiv positive or other acquired, congenital immunodeficiency disease, or organ transplant history -
smart technology facilitated patient-centered venous thromboembolism management

Conditions: Venous Thromboembolism; Digital Health; Health Education

Summary: smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. these technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. they are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention. the objective of this study is to observe the long-term effect of mobile venous thromboembolism application (mvtea) based patient-centered management of venous thromboembolism (vte) on thromboprophylaxis, and establish a foundation of evidence for managing patients with high-risk vte.


Eligibility criteria:
inclusion criteria: * inpatients ≥18 years of age at admission; * at high-risk of vte at discharge: padua score ≥4 for medical patients and caprini score ≥5 for surgical patients; * signed informed consent. exclusion criteria: * diagnosis of vte at discharge; * mental disorder or combination of other serious diseases leading to incapacity for independent living; * inability to use smartphones, computer tablets and other smart devices; * being pregnant or breastfeeding; * have participated in similar trials or are undergoing other clinical trials.

Keywords: venous thromboembolism mobile health prophylaxis health education
oral vs iv acetaminophen for long-bone fracture in children

Conditions: Pain

Summary: intravenous (iv) acetaminophen entered the canadian market recently and children with acute pain following a trauma are ideal candidates for the iv formulation as it may improve analgesia and consequently decrease the amount of opioids needed to achieve pain control. due to the limited data on bioavailability, adverse effect profile and efficacy of iv versus oral acetaminophen, it is of paramount importance to generate evidence-based data to guide clinicians with a rational choice of route of administration of acetaminophen. therefore, we propose a pilot study to inform a future large randomized controlled trial (rct) to compare pharmacokinetics, feasibility, preliminary effects and side effects profile of oral versus iv acetaminophen in children admitted for surgical fixation of a long-bone fracture.

patients admitted for a long-bone fracture needing surgical fixation are generally initially treated with intranasal and/or iv opioids in association to oral acetaminophen and ibuprofen. following surgery they are treated with a combination of morphine and acetaminophen. to address the issue of opioid epidemics, the pediatric orthopaedic society of north america recommends reduction of their prescription as much as possible by promoting, among others, use of multimodal analgesia after surgery. the current proposal aims to improve post-operative pain control in children following a surgical fixation of a long-bone fracture and decrease the use of opioids through better co-analgesia. as such, this study aims to assess the pharmacokinetics (pk) and the efficacy of oral versus iv formulations of acetaminophen after surgery for long bone fractures in children.

Eligibility criteria:
inclusion criteria: * likely to undergo surgery for a long-bone fracture * aged between 2-18 years (iv acetaminophen is approved for children ≥2 years) * iv line per standard of care exclusion criteria: * contraindication to oral drug administration * patients unable to take oral solution * known hypersensitivity or allergy to acetaminophen or any of the excipients in the iv or oral formulation * use of any medication known to interact with acetaminophen including, but not restricted to phenytoin and carbamazepine (1) * pregnancy * known hepatic insufficiency or hepatic disease * known or diagnosed severe renal failure * multiple trauma (more than two long bone fractures) * hemodynamic or respiratory compromise * altered level of consciousness (glasgow coma scale \<15)

Keywords: pain analgesics pediatrics acetaminophen orthopedics pharmacokinetics
an efficacy and safety study of cnto1959 (guselkumab) in the treatment of participants with generalized pustular psoriasis or erythrodermic psoriasis

Conditions: Pustular Psoriasis

Summary: the purpose of this study is to examine descriptively the efficacy of cnto 1959 in participants with generalized pustular psoriasis (gpp) or erythrodermic psoriasis (ep).

this is a phase 3, multicenter (when more than one hospital or medical school team work on a medical research study), open-label study evaluating the efficacy and safety of cnto1959 (guselkumab) in the treatment of participants with gpp or ep. participants will receive 50 milligram (mg) guselkumab subcutaneously at weeks 0, 4 and 12. at week 16 up to week 52 participants who will be defined "very much improved" or "much improved" in clinical global impression (cgi) will continue to receive guselkumab 50 mg every 8 weeks from week 20 to the study end (week 52). at each visit timing from week 20, participants who will be defined "no change" or "worsened" will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until week 52. participants who are "minimally improved" will also receive guselkumab 100 mg only if investigator considers it necessary. participants will primarily be assessed for the treatment success. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * have a diagnosis of generalized pustular psoriasis (gpp) or erythrodermic psoriasis (ep) at screening. a diagnosis of gpp must be classified on the basis of the criteria for diagnosis of gpp by japanese dermatological association (jda) * have a history of plaque-type psoriasis if subjects have a diagnosis of ep * have an involved body surface area (bsa) of lesion greater than or equal to (\>=) 80 percent (%) at baseline if subjects have a diagnosis of ep. * be a candidate for phototherapy or systemic treatment for psoriasis (either naïve or history of previous treatment) * before the first administration of study drug, a woman must be either not of childbearing potential or of childbearing potential and practicing a highly effective methods of birth control, consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies exclusion criteria: * has a total score of jda severity index for gpp \>=14 at baseline if subjects have a diagnosis of gpp * has a differential diagnosis of the erythroderma (exmaple (eg), erythroderma caused by lymphoma or drug eruption) other than ep. * has refused hospitalization though the investigator needed hospitalization * has body mass index (bmi) less than (\<) 18 kilogram per square meters (kg/m\^2) or meets the following modified criteria for cachexia. * has a bmi \ ) 7 mg/l 6) hemoglobin (hb) \<12 gram per deciliters (g/dl) f) serum albumin \< 3.0 g/dl * has common terminology criteria for adverse events (ctcae) version 4 grade 2 or higher heart failure or ctcae v.4 grade 3 or higher kidney failure

Keywords: generalized pustular psoriasis erythrodermic psoriasis guselkumab cnto1959